Bristol Myers Squibb gets FDA accelerated approval for Zenbexus
Bristol Myers Squibb receives U.S. FDA accelerated approval for its first CELMoD therapy, Zenbexus, combined with daratumumab and hyaluronidase-fihj and dexamethasone (ZDD), for multiple myeloma as early as first relapse.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.